Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS 1.5/30 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Oral contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily at the same time each day.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol undergoes first-pass metabolism in gut wall and liver via CYP3A4; desogestrel is metabolized by CYP2C9 and CYP2C19 to active metabolite etonogestrel.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinylestradiol: ~97% bound to albumin (90%) and SHBG (minor). 3-Keto-desogestrel: ~95% bound: albumin (65%) and SHBG (30%).
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinylestradiol: Vd ~2.5-3.0 L/kg; distributes extensively into body tissues (breast, liver). 3-Keto-desogestrel: Vd ~1.5-2.0 L/kg; moderate tissue binding.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: ethinylestradiol ~40-50% (due to first-pass metabolism); desogestrel ~76% (≥60% converted to active 3-keto-desogestrel after first pass).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
Contraindicated in patients with renal impairment (e GFR <60 m L/min/1.73 m2) due to increased risk of hyperkalemia and reduced efficacy.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) due to impaired hormone metabolism and potential for adverse effects.
No data available for fictional drug ALYACEN 777.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in females under 18 years of age.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women. Efficacy in women over 40 years of age has not been fully established; consider alternative contraception due to increased cardiovascular risk.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and smoking intensity (especially in women over 35).
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders (e.g., DVT, PE),Myocardial infarction and stroke risk,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Ocular lesions,Dose-related risk of VTE from desogestrel-containing pills
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Hepatic adenoma or carcinoma,Active liver disease with abnormal function
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions. Grapefruit juice does not significantly interact with ethinylestradiol or gestodene. St. John's Wort (Hypericum perforatum) reduces contraceptive efficacy by inducing CYP3A4 metabolism; avoid concurrent use. High-fat meals may increase ethinylestradiol absorption slightly but no dose adjustment needed.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: Combination oral contraceptives are not associated with a major increase in risk of birth defects. Second and third trimesters: Prolonged use may be associated with fetal harm including cardiovascular and skeletal anomalies, though data are limited. Known pregnancy contraindicates use.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Ethinyl estradiol and levonorgestrel are excreted in breast milk in small amounts. M/P ratio not established. Potential for adverse effects in nursing infant, including reduced milk production and jaundice. Use not recommended in breastfeeding women.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Contraindicated in pregnancy. No dose adjustments applicable; use should be discontinued immediately if pregnancy occurs.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
GILDESS 1.5/30 is a combined oral contraceptive (COC) containing ethinylestradiol 30 µg and gestodene 75 µg. Gestodene is a third-generation progestin with high progestogenic activity and low androgenic effects, reducing acne and hirsutism. This formulation has a higher risk of venous thromboembolism (VTE) compared to second-generation COCs. Avoid in women with migraines with aura, hypertension (BP >160/100), or BMI >30 due to increased VTE risk. For missed pills: if one pill is missed, take it as soon as remembered and continue; if two or more pills are missed, take the last missed pill, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, preferably in the evening, to reduce nausea.,If you miss a pill, follow the instructions in the package leaflet; if you miss more than one pill, use additional contraception (e.g., condoms) for 7 days.,Smoking increases the risk of serious cardiovascular side effects; do not smoke while taking this medication, especially if you are over 35.,Tell your doctor if you experience severe headache, chest pain, leg pain or swelling, visual disturbances, or jaundice.,This medication does not protect against sexually transmitted infections; use condoms for additional protection.,Vomiting or severe diarrhea within 4 hours of taking the pill reduces efficacy; consider it as a missed pill and use backup contraception.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS 1.5/30 vs ALYACEN 777, answered by our medical review team.
GILDESS 1.5/30 is a Oral Contraceptive that works by Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS 1.5/30 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS 1.5/30 is: One tablet orally once daily at the same time each day.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS 1.5/30 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS 1.5/30 is classified as Category C. First trimester: Combination oral contraceptives are not associated with a major increase in risk of birth defects. Second and third trimesters: Prolonged use may be associated wit. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.